Cullen Capital Management LLC Acquires 36,714 Shares of Sanofi $SNY

Cullen Capital Management LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 9.2% in the second quarter, Holdings Channel.com reports. The institutional investor owned 437,824 shares of the company’s stock after acquiring an additional 36,714 shares during the period. Cullen Capital Management LLC’s holdings in Sanofi were worth $21,151,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Capital Analysts LLC grew its position in Sanofi by 14.0% in the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after acquiring an additional 204 shares during the last quarter. Thomasville National Bank grew its holdings in shares of Sanofi by 0.3% during the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock valued at $3,886,000 after purchasing an additional 211 shares during the last quarter. CreativeOne Wealth LLC grew its holdings in shares of Sanofi by 2.8% during the 2nd quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock valued at $434,000 after purchasing an additional 241 shares during the last quarter. U.S. Capital Wealth Advisors LLC increased its position in Sanofi by 4.1% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock worth $301,000 after purchasing an additional 247 shares in the last quarter. Finally, Whipplewood Advisors LLC lifted its stake in Sanofi by 18.2% in the 2nd quarter. Whipplewood Advisors LLC now owns 1,606 shares of the company’s stock valued at $78,000 after purchasing an additional 247 shares during the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. HSBC reiterated a “buy” rating on shares of Sanofi in a research report on Wednesday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $62.67.

Sanofi Trading Down 0.4%

NASDAQ SNY opened at $48.68 on Monday. The business’s 50-day moving average price is $49.87 and its two-hundred day moving average price is $49.02. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The firm has a market capitalization of $119.53 billion, a PE ratio of 11.40, a price-to-earnings-growth ratio of 1.33 and a beta of 0.44. The company has a current ratio of 1.06, a quick ratio of 0.30 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. The company had revenue of $15.46 billion during the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm’s revenue was down 7.5% compared to the same quarter last year. During the same period last year, the company earned $2.25 earnings per share. On average, analysts expect that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.